Osiris Therapeutics, Inc. (A subsidiary of Smith+Nephew), JCR Pharmaceuticals Co., Ltd, Orthofix Medical Inc. dominated the Global Stem Cell Therapy Market in 2021

The Global Stem Cell Therapy Market is expected to grow with a CAGR of 9.7% in the forecast period of 2022 to 2029. The years considered for the study are as mentioned below:

Access Full Report @ https://www.databridgemarketresearch.com/reports/global-stem-cell-therapy-market

The global stem cell therapy market is a highly consolidated market, which includes a specific number of key players. The market has witnessed increased strategic developments owing to a favorable market scenario.  

The major players dealing in the global stem cell therapy market are introducing a strong range of products provider along with launching new products and adopting strategic initiatives such as acquisition, agreement, business expansion, awards, and recognition into the market. This helped companies to maximize sales with an enhanced product portfolio.  

For instance,

  • In October 2021, Orthofix Medical Inc. formed an agreement with MTF Biologics. The agreement extended Orthofix's exclusive marketing rights to the Trinity allograft line through 2032 and entailed an expansion agreement for the development of a demineralized bone matrix (DBM), which Orthofix Medical Inc. will market under the legacy brand name.

Osiris Therapeutics, Inc. (A subsidiary of Smith+Nephew) is the dominating player in the global stem cell therapy market. Some of the other key players existing in the market are JCR Pharmaceuticals Co., Ltd, Orthofix Medical Inc., MEDIPOST, Takeda Pharmaceutical Company Limited, CORESTEM, Inc., PHARMICELL Co., Ltd., STEMPEUTICS RESEARCH PVT LTD, ANTEROGEN.CO., LTD, Holostem, Terapie Avanzate S.r.l., U.S. Stem Cell, Inc, BrainStorm Cell Limited, Pluristem Inc., International Stem Cell Corporation, Mesoblast Ltd, Athersys, Inc., BioRestorative Therapies, Inc., among others.

Osiris Therapeutics, Inc. (A subsidiary of Smith+Nephew)

Osiris Therapeutics, Inc. (A subsidiary of Smith+Nephew) is headquartered in Maryland, the U.S., and was founded in 1992. It has private ownership. The company focuses on developing and marketing products to treat medical conditions. The company has various business segments such as Orthopedics, Sports Medicine & ENT, and Advanced Wound Management, out of which Advanced Wound Management is the market-focused segment. The product of the company includes GRAFIX-PL, which is also market-focused. 

For instance,

  • In March 2019, Osiris Therapeutics Inc and Smith+Nephew expanded the product portfolio of regenerative medicine and wounds and chronic management by the launch of Grafix-PL after the acquisition of Osiris Therapeutics Inc. The expansion had resulted in an enhanced product portfolio with strong clinical evidence addressing critical needs in the marketplace. It increased the stem cell market growth

The company has a global presence in North America.

JCR Pharmaceuticals Co., Ltd

JCR Pharmaceuticals Co., Ltd is headquartered in Japan and was founded in 1975. It has public ownership. The company focuses on researching, developing, and marketing regenerative medicine and biopharmaceuticals for rare diseases. The company operates in various product categories such as Growth Hormone, Lysosomal Disease, Renal Anemia, and Regenerative Medical Products, out of which Regenerative Medical Products is the market-focused category.

The company has a presence across North America, Europe, and Asia-Pacific. In addition, the company also generates its revenue from various subsidiaries, including ArmaGen (U.S.), JCR USA, Inc (U.S.), Chromatech Co., Ltd. (Japan), JCR Engineering Co., Ltd. (Japan), JCR INTERNATIONAL SA (Switzerland), among others.

Stem Cell Therapy Market

Orthofix Medical Inc.

Orthofix Medical Inc. is headquartered in Texas, the U.S., and was founded in 1980. It has public ownership. The company focuses on improving patients' lives through superior reconstruction, biologics, and regenerative spine and extremity solutions. The company has various business segments, such as Biologics, Bone Growth Therapies, and Spinal Implants, out of which Biologics is the market-focused segment. The various product categories of the company include Motion Preservation, Spine Fixation, Biologics, Bone Growth Therapy, and Biologics, out of which Biologics is the market-focused category.

For instance,

  • In February 2022, Orthofix Medical Inc. announced the expansion of Trinity Elite and Trinity Evolution allografts with viable cells. The expansion would improve the biologics product range and increase revenue

The company has a presence across North America, Europe, and Asia-Pacific. In addition, the company also generates its revenue from various subsidiaries, including S Breg, Inc.(U.S.), Orthofix US LLC (U.S.), Spinal Kinetics GmbH (U.S.), Orthofix GmbH (Germany), Spinal Kinetics LLC (U.S.), among others.